☆ 4.4 Article

The anti-Candida albicans vaccine composed of the recombinant N terminus of Als1p reduces fungal burden and improves survival in both immunocompetent and immunocompromised mice

INFECTION AND IMMUNITY (2005)

Get Full Text
Add to Collection

Journal

INFECTION AND IMMUNITY
Volume 73, Issue 9, Pages 6191-6193

Publisher

AMER SOC MICROBIOLOGY
DOI: 10.1128/IAI.73.9.6191-6193.2005

Keywords

-

Categories

Immunology Infectious Diseases

Funding

  1. NIAID NIH HHS [KO8 AI060641, K08 AI060641, P01 AI037194, R01 AI19990, P01 AI37194, R03 AI054531, R01 AI019990] Funding Source: Medline
  2. NIDCR NIH HHS [R01 DE013974] Funding Source: Medline
  3. PHS HHS [R01 A1054928] Funding Source: Medline

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

We have previously shown that intraperitoneal vaccination with the recombinant N terminus of Als1p (rAls1p-N) modestly improves survival during murine disseminated candidiasis. We now report marked efficacy with subcutaneous rAls1p-N vaccination. Efficacy is retained in neutropenic and corticosteroid-treated mice. The rAls1p-N vaccine is a promising candidate for the prevention of invasive candidiasis.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.